1. Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users 
Aimin Li, M.D., Juan C. Felix, M.D., Wangrong Yang, M.Sc., John K. Jain, M.D. 
Fertility and Sterility 
Volume 90, Issue 3, Pages (September 2008)
DOI: /j.fertnstert
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Immunohistochemical staining for secretory leukocyte protease inhibitor (SLPI) in endometrium of a woman from the placebo group (P) and a woman from the mifepristone group (M). (A) Pretreatment endometrium. Note SLPI-positive staining in glands. (B) After 14 days of depot medroxyprogesterone acetate (DMPA) injection. Note SLPI immunoreactivity reduced in the glandular compartment. (C) After 1 week of placebo. (D) After 10 weeks of placebo. (E) Pretreatment endometrium. (F) After 14 days of DMPA injection. (G) After 1 week of mifepristone. (H) After 10 weeks of mifepristone. Note the increase of SLPI immunoreactivity in glands. 1st, 2nd, 3rd, and 4th indicate the biopsy numbers.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions